Long-term safety study of Livmarli for Alagille syndrome or PFIC
Part of Digestive system, Genetic & congenital, Heart & circulation, Skin clinical trials.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Alagille syndrome or PFIC, confirmed by a doctor or genetic test.
- You have itching caused by liver problems.
- If you have Alagille syndrome, you must be at least 2 months old to start Livmarli.
- If you have PFIC, you must be at least 3 months old to start Livmarli.
- You have never had a liver transplant.
- You have not taken another IBAT inhibitor medicine within 7 days before starting Livmarli.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
This study follows patients with Alagille syndrome who are taking odevixibat to see how safe the medicine is over time. Alagille syndrome is a rare liver disease that affects bile flow, and odevixibat is a treatment that may help reduce itching and improve liver function.
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
This study looks at how well Livmarli works for people with Alagille syndrome or a liver disease called PFIC. It uses data from prescriptions to understand the treatment's effects.
Hear when a new Alagille Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.